Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24295356 | 0.86 | — | — | |
| SCHEMBL20154933 | 0.82 | TSHR (0.40) | GABRA1GABRB2TSHR | |
| SCHEMBL18610692 | 0.80 | — | — | |
| SCHEMBL22304506 | 0.80 | — | — | |
| SCHEMBL12263257 | 0.80 | — | — | |
| SCHEMBL23339992 | 0.80 | — | — | |
| SCHEMBL15979646 | 0.80 | — | — | |
| SCHEMBL23424237 | 0.80 | — | — | |
| SCHEMBL22435583 | 0.80 | — | — | |
| SCHEMBL13919743 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116948065-A | Solid catalyst component for olefin polymerization, preparation method thereof and catalyst containing solid catalyst component | 中国石油天然气股份有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2024-02-29 | — | — | US | disclosed |
| CN-116948065-A | Solid catalyst component for olefin polymerization, preparation method thereof and catalyst containing solid catalyst component | 中国石油天然气股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023118576-A1 | DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE | IMMUNIC AG (DE) | 2023-06-29 | — | — | WO | disclosed |
| US-20220117969-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADENOMYOSIS AND RECTOVAGINAL ENDOMETRIOSIS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| US-20210206791-A1 | SELECTIVE METAL-MEDIATED ARYLATION OF DICHALCOGENIDES IN BIOMOLECULES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-07-08 | — | — | US | disclosed |
| US-20200405887-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200138819-A1 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR THE TREATMENT OF ENDOMETRIOSIS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20100004256-A1 | HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090299060-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7612218-B2 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7572784-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572784-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | GABRA1 4822/4885GABRB1 4811/4885GABRB2 4817/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | GABRA1 691/4885GABRB1 792/4885GABRB2 985/4885 |
| US-20200138819-A1 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR THE TREATMENT OF ENDOMETRIOSIS | GNRHR, FSHR, LHCGR | GABRA1 1428/4885GABRB1 865/4885GABRB2 762/4885 |
| US-20220117969-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADENOMYOSIS AND RECTOVAGINAL ENDOMETRIOSIS | GNRHR, PGR, NR5A1 | GABRA1 4174/4885GABRB1 3725/4885GABRB2 3949/4885 |
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | GABRA1 2667/4885GABRB1 3343/4885GABRB2 2987/4885 |
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | AURKB, AURKC, AURKA | GABRA1 4405/4885GABRB1 3978/4885GABRB2 3946/4885 |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | GABRA1 2667/4885GABRB1 3343/4885GABRB2 2987/4885 |
| US-20100004256-A1 | HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES | CDK2, DPYD, CCNB1 | GABRA1 2949/4885GABRB1 2880/4885GABRB2 3160/4885 |
| US-20090299060-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | GABRA1 4822/4885GABRB1 4811/4885GABRB2 4817/4885 |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | GABRA1 246/4885GABRB1 93/4885GABRB2 141/4885 |
| US-20210206791-A1 | SELECTIVE METAL-MEDIATED ARYLATION OF DICHALCOGENIDES IN BIOMOLECULES | SCLY, SELENOI, PTMS | GABRA1 4324/4885GABRB1 4257/4885GABRB2 3971/4885 |
| US-20200405887-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | GABRA1 2667/4885GABRB1 3343/4885GABRB2 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.